Last reviewed · How we verify
Arnica montana Topical Gel
Arnica montana Topical Gel is a Small molecule drug developed by Universidad del Valle de México, Campus Cuernavaca. It is currently in Phase 1 development.
At a glance
| Generic name | Arnica montana Topical Gel |
|---|---|
| Sponsor | Universidad del Valle de México, Campus Cuernavaca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Home-Based Quadriceps Isometric Exercise for Knee Osteoarthritis Pain (NA)
- Evaluation of the Use of Ozone Gel Versus Hyaluronic Acid Gel on Palatal Wound Healing . (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arnica montana Topical Gel CI brief — competitive landscape report
- Arnica montana Topical Gel updates RSS · CI watch RSS
- Universidad del Valle de México, Campus Cuernavaca portfolio CI
Frequently asked questions about Arnica montana Topical Gel
What is Arnica montana Topical Gel?
Arnica montana Topical Gel is a Small molecule drug developed by Universidad del Valle de México, Campus Cuernavaca.
Who makes Arnica montana Topical Gel?
Arnica montana Topical Gel is developed by Universidad del Valle de México, Campus Cuernavaca (see full Universidad del Valle de México, Campus Cuernavaca pipeline at /company/universidad-del-valle-de-m-xico-campus-cuernavaca).
What development phase is Arnica montana Topical Gel in?
Arnica montana Topical Gel is in Phase 1.